Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)

5 de octubre de 2026 actualizado por: University of California, San Francisco

Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa

The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.

The main questions it aims to answer are:

  • Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa?
  • Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?

Participants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.

Participants will:

  • Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility
  • Engage in close reading of visual or written texts
  • Complete creative writing exercises in response to prompts
  • Participate in group discussions and sharing

An optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.

This study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

10

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • San Francisco, California, Estados Unidos, 94158
        • Reclutamiento
        • UCSF Nancy Friend Pritzker Psychiatry Building
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

16 años a 25 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 16-25 years old
  • have a DSM-5 diagnosis of AN (confirmed by the UCSF Eating Disorders Program clinical team),
  • currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention
  • English fluency to engage in reflective writing and discussions
  • Cognitive ability to meaningfully participate in narrative-based exercises

Exclusion Criteria:

  • Currently medically unstable or require inpatient hospitalization
  • History of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder
  • Severe neurocognitive impairment that would prevent engagement with the intervention
  • Active suicidal ideation or non-suicidal self-injury within the past two months
  • Insufficient English proficiency to participate in group discussions and writing exercises

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Narrative Medicine (NM) Workshop Series

Participants in this study will take part in a six-week Narrative Medicine (NM) curriculum designed to enhance self-expression, reflection, and resilience in individuals with anorexia nervosa. Workshops will be conducted weekly on Zoom and will include:

  • Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility
  • Creative writing exercises in response to structured prompts
  • Group discussions and sharing to foster community, connection, and self-expression

The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools.

Each one-hour weekly workshop includes:

  • Close reading of visual or written texts related to themes such as self-definition, resilience, kindness, and possibility
  • Creative writing exercises in response to structured prompts that encourage self-reflection and personal storytelling
  • Facilitated group discussions to foster connection, self-expression, and emotional processing in a supportive environment

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants in each session
Periodo de tiempo: Immediately post-intervention (Week 6)

Feasibility will be measured by participant retention in intervention.

Immediately post-intervention (Week 6)
Satisfaction with intervention components using 5-point Likert scales and semi-structured individual interviews
Periodo de tiempo: Immediately post-intervention (Week 6)

Acceptability will be measured by questionnaire including 5-point Likert scales and semi-structured individual interviews assessing content relevance, writing prompts, group discussions, and facilitation.

Scale title: Intervention Satisfaction Questionnaire (ISQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Higher scores indicate greater satisfaction with the intervention (better outcome).

Immediately post-intervention (Week 6)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Illness-Identity Centrality
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)

Assessed using the Illness Identity Questionnaire, which evaluates self-concept clarity and personal identity coherence.

Scale title: Illness Identity Questionnaire (IIQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Subscale scores reflect distinct illness identity states; higher scores indicate greater endorsement of that identity orientation

Pre- (Week 0) and immediately post-intervention (Week 6)
Social Connectedness
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)

Measured using the Social Connectedness Scale (SCS), which assesses perceived closeness to others and sense of belonging.

Scale title: Social Connectedness Scale (SCS) Minimum value: 1 (Strongly Disagree) Maximum value: 6 (Strongly Agree) Interpretation: Higher scores indicate greater feelings of social connectedness and belonging (better outcome).

Pre- (Week 0) and immediately post-intervention (Week 6)
Depression Symptoms
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)

Measured using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms.

Scale title: Patient Health Questionnaire-9 (PHQ-9) Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of depressive symptoms (worse outcome).

Pre- (Week 0) and immediately post-intervention (Week 6)
Anxiety Symptoms
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)

Measured using the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.

Scale title: Generalized Anxiety Disorder 7-item (GAD-7) Scale Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of anxiety symptoms (worse outcome).

Pre- (Week 0) and immediately post-intervention (Week 6)
Eating Disorder Severity
Periodo de tiempo: Pre- (Week 0) and immediately post-intervention (Week 6)

Measured using the Eating Disorder Examination Questionnaire (EDE-Q), which captures cognitive and behavioral symptoms of AN, and percent of expected body weight (EBW) at follow-up.

Scale title: Eating Disorder Examination Questionnaire (EDE-Q) Minimum value: 0 (No days / Not at all) Maximum value: 6 (Every day / Extremely) Interpretation: Higher scores indicate greater severity of eating disorder psychopathology (worse outcome).

Pre- (Week 0) and immediately post-intervention (Week 6)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Anoushka Sinha, MD, MS, University of California, San Francisco

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de octubre de 2026

Finalización primaria (Estimado)

1 de julio de 2027

Finalización del estudio (Estimado)

1 de julio de 2027

Fechas de registro del estudio

Enviado por primera vez

5 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

5 de mayo de 2026

Publicado por primera vez (Actual)

12 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 24-43017 (b)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .